Crinetics Pharmaceuticals, Inc. Share Price
Stocks
CRNX
US22663K1079
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.90 USD | +0.04% |
|
+0.23% | +80.24% |
| 08/07 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 07/07 | IBT company Crinetics to be acquired by Vertex for USD10 billion | AN |
| Market Cap | 884.64Cr 775.39Cr 718.45Cr 661.27Cr 1.25TCr 85TCr 1.26TCr 8.57TCr 3.36TCr 42TCr 3.32TCr 3.25TCr 1,44200Cr | P/E 2026 * |
-17.8x | P/E 2027 * | -20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 781.14Cr 684.67Cr 634.39Cr 583.9Cr 1.1TCr 75TCr 1.11TCr 7.57TCr 2.96TCr 37TCr 2.93TCr 2.87TCr 1,27300Cr | EV / Sales 2026 * |
114x | EV / Sales 2027 * | 46.4x |
| Free-Float |
98.21% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Crinetics Pharmaceuticals, Inc.
| 1 day | +0.04% | ||
| 1 week | +0.23% | ||
| Current month | +124.21% | ||
| 1 month | +133.90% | ||
| 3 months | +115.68% | ||
| 6 months | +51.42% | ||
| Current year | +80.24% |
| 1 week | 83.8 |  | 84 |
| 1 month | 34.7 | | 84 |
| Current year | 32.3 | | 84 |
| 1 year | 25.83 | | 84 |
| 3 years | 15.76 | | 84 |
| 5 years | 15.23 | | 84 |
| 10 years | 10.63 | | 84 |
| Manager | Title | Age | Since |
|---|---|---|---|
R. Struthers
CEO | Chief Executive Officer | 64 | 01/12/2008 |
Stephen Betz
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/10/2021 |
Tobin Schilke
DFI | Director of Finance/CFO | 51 | 28/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Wendell Wierenga
CHM | Chairman | 78 | 01/10/2015 |
R. Struthers
BRD | Director/Board Member | 64 | 01/11/2008 |
Matthew Fust
BRD | Director/Board Member | 61 | 01/02/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/07/26 | Sell | Director | -3,000 | 0.0028% | ||
| 18/06/26 | Free | Director | 15,655 | 0.0148% | ||
| 18/06/26 | Free | Director | 15,655 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.04% | +0.23% | +171.08% | +348.42% | 884.64Cr | |
| +1.80% | -0.83% | +52.79% | +86.50% | 5.56TCr | |
| -0.11% | +1.28% | +56.13% | +58.74% | 5.43TCr | |
| +0.18% | +2.13% | -15.22% | -14.97% | 2.33TCr | |
| +1.50% | -1.35% | +5.68% | +415.28% | 2.35TCr | |
| +0.05% | -1.77% | +38.71% | -4.22% | 2.03TCr | |
| +1.32% | -1.03% | +35.49% | -30.35% | 1.74TCr | |
| +1.08% | -3.63% | +36.77% | +547.87% | 1.56TCr | |
| 0.00% | -2.08% | +165.40% | +297.92% | 1.5TCr | |
| +1.06% | +0.63% | +26.80% | +185.02% | 1.41TCr | |
| Average | +0.70% | -0.94% | +57.36% | +189.02% | 2.48TCr | |
| Weighted average by Cap. | +0.79% | -1.16% | +48.81% | +143.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.85Cr 6Cr 5.56Cr 5.12Cr 9.65Cr 659.63Cr 9.77Cr 66Cr 26Cr 323.28Cr 26Cr 25Cr 1.12TCr | 17Cr 15Cr 14Cr 13Cr 24Cr 1.66TCr 25Cr 166.9Cr 65Cr 812.71Cr 65Cr 63Cr 2.81TCr |
| Net income | -52Cr -45Cr -42Cr -39Cr -73Cr -4.97TCr -74Cr -500.62Cr -195.9Cr -2.44TCr -193.88Cr -189.71Cr -8.42TCr | -47Cr -41Cr -38Cr -35Cr -67Cr -4.55TCr -67Cr -458.07Cr -179.25Cr -2.23TCr -177.4Cr -173.58Cr -7.7TCr |
| Net Debt | -103.51Cr -91Cr -84Cr -77Cr -145.9Cr -9.97TCr -147.66Cr -1TCr -392.6Cr -4.89TCr -388.54Cr -380.18Cr -17TCr | -87Cr -76Cr -70Cr -65Cr -121.95Cr -8.33TCr -123.43Cr -838.62Cr -328.17Cr -4.08TCr -324.78Cr -317.79Cr -14TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $83.90 | +0.04% | 27,34,950 |
| 20/26/20 | $83.87 | +0.01% | 36,02,088 |
| 17/26/17 | $83.86 | -0.06% | 53,73,712 |
| 16/26/16 | $83.91 | +0.01% | 36,16,056 |
| 15/26/15 | $83.90 | +0.23% | 35,31,273 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRNX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition